Protocol Ledger

NCT05393791 · Phase II · RECRUITING

Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC

Interventional Phase II clinical trial protocol NCT05393791 sponsored by Leiden University Medical Center in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-11-10 Enrollment: 168 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05393791
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)168 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05393791
Protocol FieldVerified Registry Value
NCT IdentifierNCT05393791
Consolidated Lead SponsorLeiden University Medical Center
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment168 participants (ESTIMATED)
Registered Start Date2022-11-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05393791
Hospital Research SiteLocationSite Profile
Chris O'Brien LifehouseCamperdown, AustraliaOpen Hospital Dossier ->
Sunshine Coast University HospitalBirtinya, AustraliaOpen Hospital Dossier ->
Royal Adelaide HospitalAdelaide, AustraliaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI